IRTC:NSD-iRhythm Technologies Inc. (USD)

EQUITY | Medical Devices | NASDAQ Global Market

Last Closing

USD 100.34

Change

0.00 (0.00)%

Market Cap

USD 0.62B

Volume

0.41M

Analyst Target

USD 222.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-06 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+6.15 (+10.13%)

USD 23.46B
PODD Insulet Corporation

+17.68 (+7.16%)

USD 17.22B
MASI Masimo Corporation

+19.51 (+13.45%)

USD 7.80B
BRKR Bruker Corporation

+4.83 (+13.28%)

USD 5.53B
PRCT Procept Biorobotics Corp

+5.86 (+12.00%)

USD 3.27B
QDEL Quidel Corporation

+2.65 (+10.11%)

USD 2.42B
TMDX TransMedics Group Inc

+7.46 (+10.98%)

USD 2.27B
LIVN LivaNova PLC

+1.87 (+5.52%)

USD 1.95B
NVCR Novocure Ltd

+1.58 (+10.28%)

USD 1.81B
UFPT UFP Technologies Inc

+18.71 (+9.68%)

USD 1.62B

ETFs Containing IRTC

EDOC:LSE Global X Telemedicine & D.. 4.35 % 0.00 %

-0.24 (0%)

USD 4.95M
EDOG:LSE Global X Telemedicine & D.. 4.35 % 0.00 %

-0.21 (0%)

USD 0.33M
FDHT:XETRA 2.58 % 0.00 %

N/A

N/A
KOMP SPDR Kensho New Economies.. 0.00 % 0.00 %

+3.98 (+0%)

USD 2.02B
SLIM 0.00 % 0.50 %

N/A

N/A
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

+5.37 (+0%)

USD 0.18B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.28% 90% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.28% 90% A- 90% A-
Trailing 12 Months  
Capital Gain -10.22% 74% C 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.22% 74% C 51% F
Trailing 5 Years  
Capital Gain 33.68% 83% B 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.68% 83% B 51% F
Average Annual (5 Year Horizon)  
Capital Gain -1.12% 45% F 37% F
Dividend Return -1.12% 45% F 33% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 59.75% 53% F 31% F
Risk Adjusted Return -1.88% 44% F 35% F
Market Capitalization 0.62B 96% N/A 85% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 36.10 4% 4%
Price / Cash Flow Ratio 968.14 2% 0%
Price/Free Cash Flow Ratio -34.37 96% 96%
Management Effectiveness  
Return on Equity -75.27% 46% 25%
Return on Invested Capital -23.63% 51% 33%
Return on Assets -6.54% 72% 39%
Debt to Equity Ratio 711.10% 5% 3%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector